Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$20.95
-1.4%
$20.14
$13.40
$25.23
$3.55B0.641.97 million shs916,956 shs
Arcellx, Inc. stock logo
ACLX
Arcellx
$67.30
+1.4%
$63.15
$47.86
$107.37
$3.66B0.28609,990 shs166,184 shs
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$4.30
+2.5%
$3.94
$3.21
$7.18
$1.00B0.64.40 million shs2.84 million shs
Merus N.V. stock logo
MRUS
Merus
$53.84
+1.0%
$49.68
$33.19
$62.98
$3.69B1738,077 shs222,443 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
-0.56%-5.60%-1.07%+31.76%+34.09%
Arcellx, Inc. stock logo
ACLX
Arcellx
+2.55%+3.61%+7.12%+6.25%+24.58%
Ardelyx, Inc. stock logo
ARDX
Ardelyx
+7.44%+15.43%+8.83%-11.60%-20.64%
Merus N.V. stock logo
MRUS
Merus
+1.27%-1.02%-8.88%+27.80%+0.45%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
4.6934 of 5 stars
4.43.00.00.03.14.22.5
Arcellx, Inc. stock logo
ACLX
Arcellx
2.8098 of 5 stars
3.53.00.00.02.62.50.0
Ardelyx, Inc. stock logo
ARDX
Ardelyx
4.3695 of 5 stars
3.53.00.04.41.92.50.6
Merus N.V. stock logo
MRUS
Merus
1.4798 of 5 stars
3.61.00.00.00.02.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
2.71
Moderate Buy$27.8833.05% Upside
Arcellx, Inc. stock logo
ACLX
Arcellx
3.07
Buy$111.2365.29% Upside
Ardelyx, Inc. stock logo
ARDX
Ardelyx
3.00
Buy$10.89153.52% Upside
Merus N.V. stock logo
MRUS
Merus
3.14
Buy$84.6457.20% Upside

Current Analyst Ratings Breakdown

Latest ARDX, MRUS, ACLX, and ACAD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform$19.00 ➝ $22.00
6/26/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$37.00
6/26/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
6/26/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00
6/23/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$26.00 ➝ $38.00
6/18/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
6/17/2025
Arcellx, Inc. stock logo
ACLX
Arcellx
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Buy$110.00
6/16/2025
Arcellx, Inc. stock logo
ACLX
Arcellx
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$115.00
6/6/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$26.00 ➝ $30.00
6/5/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/5/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Hold$18.00 ➝ $23.00
(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$957.80M3.66$0.70 per share30.13$4.40 per share4.76
Arcellx, Inc. stock logo
ACLX
Arcellx
$107.94M34.36N/AN/A$8.41 per share8.00
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$333.61M3.08N/AN/A$0.73 per share5.88
Merus N.V. stock logo
MRUS
Merus
$36.13M103.13N/AN/A$9.46 per share5.69
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$226.45M$1.3715.2927.574.5822.97%17.46%10.75%8/5/2025 (Estimated)
Arcellx, Inc. stock logo
ACLX
Arcellx
-$107.35M-$2.99N/AN/AN/A-211.46%-35.27%-22.73%8/14/2025 (Estimated)
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$39.14M-$0.22N/A13.85N/A-14.86%-34.45%-13.81%7/30/2025 (Estimated)
Merus N.V. stock logo
MRUS
Merus
-$215.33M-$4.08N/AN/AN/A-506.73%-35.99%-29.83%7/30/2025 (Estimated)

Latest ARDX, MRUS, ACLX, and ACAD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Merus N.V. stock logo
MRUS
Merus
-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million
5/8/2025Q1 2025
Arcellx, Inc. stock logo
ACLX
Arcellx
-$0.84-$1.13-$0.29-$1.13$19.51 million$8.13 million
5/7/2025Q1 2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.10$0.11+$0.01$0.11$239.32 million$244.32 million
5/1/2025Q1 2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$0.10-$0.17-$0.07-$0.17$79.40 million$74.11 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/AN/AN/AN/AN/A
Arcellx, Inc. stock logo
ACLX
Arcellx
N/AN/AN/AN/AN/A
Ardelyx, Inc. stock logo
ARDX
Ardelyx
N/AN/AN/AN/AN/A
Merus N.V. stock logo
MRUS
Merus
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/A
2.88
2.80
Arcellx, Inc. stock logo
ACLX
Arcellx
N/A
4.93
4.93
Ardelyx, Inc. stock logo
ARDX
Ardelyx
1.04
4.12
3.81
Merus N.V. stock logo
MRUS
Merus
N/A
5.86
5.86

Institutional Ownership

CompanyInstitutional Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
96.71%
Arcellx, Inc. stock logo
ACLX
Arcellx
96.03%
Ardelyx, Inc. stock logo
ARDX
Ardelyx
58.92%
Merus N.V. stock logo
MRUS
Merus
96.14%

Insider Ownership

CompanyInsider Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
26.50%
Arcellx, Inc. stock logo
ACLX
Arcellx
8.35%
Ardelyx, Inc. stock logo
ARDX
Ardelyx
4.80%
Merus N.V. stock logo
MRUS
Merus
4.57%
CompanyEmployeesShares OutstandingFree FloatOptionable
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
510167.36 million123.01 millionOptionable
Arcellx, Inc. stock logo
ACLX
Arcellx
8055.11 million50.51 millionOptionable
Ardelyx, Inc. stock logo
ARDX
Ardelyx
90239.26 million227.77 millionOptionable
Merus N.V. stock logo
MRUS
Merus
3769.21 million66.05 millionOptionable

Recent News About These Companies

Merus N.V.: Making Progress
Why Merus N.V. (MRUS) Crashed On Wednesday
Merus Shares Slide on Stock Offering

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACADIA Pharmaceuticals stock logo

ACADIA Pharmaceuticals NASDAQ:ACAD

$20.95 -0.29 (-1.37%)
Closing price 03:39 PM Eastern
Extended Trading
$20.95 0.00 (0.00%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Arcellx stock logo

Arcellx NASDAQ:ACLX

$67.30 +0.96 (+1.44%)
Closing price 03:11 PM Eastern
Extended Trading
$67.30 0.00 (0.00%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Ardelyx stock logo

Ardelyx NASDAQ:ARDX

$4.30 +0.11 (+2.51%)
Closing price 03:54 PM Eastern
Extended Trading
$4.30 0.00 (0.00%)
As of 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Merus stock logo

Merus NASDAQ:MRUS

$53.84 +0.51 (+0.96%)
Closing price 01:04 PM Eastern
Extended Trading
$53.38 -0.46 (-0.85%)
As of 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.